shu-508 and Mitral-Valve-Insufficiency

Ultrasound contrast media increase backscatter from blood, thus improving the signal-to-noise ratio. Potential clinical applications of intravenous ultrasound contrast are reviewed. Contrast enhancement of continuous wave Doppler is indicated when the native recordings are noisy and no complete envelope of the Doppler spectrum is obtained. In aortic stenosis several investigations showed good agreement between the gradient calculated from Doppler measurements and the results of cardiac catheterization. In mitral insufficiency maximum area of the regurgitant jet is a widely used parameter for estimation of the severity of the regurgitation. However, assessment of the maximum jet area may not be possible because of poor acoustic windows. Contrast enhancement provides complete display of the regurgitant jet in most of the patients. The diagnostic confidence of the Doppler investigation is further improved by the recording of the pulmonary venous flow, which can be recorded in most of the patients following contrast injection. Therefore contrast enhanced transthoracic Doppler is an alternative to transesophageal Doppler investigation in patients with poor transthoracic windows.

Topics: Aortic Valve Stenosis; Artifacts; Blood Flow Velocity; Contrast Media; Echocardiography, Doppler; Echocardiography, Doppler, Color; Humans; Injections, Intravenous; Mitral Valve Insufficiency; Polysaccharides

A multicenter study was carried out to evaluate the efficacy with which SHU 508A enhances left heart Doppler signals and improves the clinical quantification of valve disease.. Poor signal-to-noise ratio often limits the Doppler interrogation of left heart flows. This problem may be resolved by the enhancement of Doppler signals by an ultrasound contrast agent capable of pulmonary transmission, such as the recently developed SHU 508A.. Left heart contrast enhancement was tested for 1) continuous wave Doppler evaluation in 51 patients with aortic stenosis, 2) pulsed Doppler transthoracic evaluation of pulmonary venous flow in 85 patients, and 3) color Doppler evaluation of mitral regurgitation in 60 patients. Studies were performed immediately before and during the intravenous administration of SHU 508A (16 ml of 200 mg/ml) and compared with unenhanced transesophageal data in representative subsets of patients.. SHU 508A had no serious adverse effects. A significant increase in left heart Doppler signal intensity lasted for 30 to 300 s. The continuous wave Doppler velocity envelope was enhanced for all jets, but Doppler peak velocity was not altered in high quality baseline studies. However, Doppler contrast enhancement resulted in higher measured peak gradients (p < 0.001) in 29 patients with aortic stenosis who had poor quality baseline studies. This improved the overall correlation with invasive pressure measurements (r = 0.73 vs. r = 0.89, p < 0.01). The enhanced pulsed Doppler traces of transthoracic pulmonary venous flow allowed quantitative analysis in 92% patients (vs. 27% at baseline) and correlated well with peak velocities and velocity profiles obtained by transesophageal echocardiography (r = 0.91, p < 0.001). The enhanced color Doppler display of regurgitant jets increased jet area with a high interindividual variability (mean 276%), resulting in almost identical jet areas as unenhanced transesophageal values (r = 0.97, p < 0.001).. SHU 508A is a safe transpulmonary contrast agent that significantly enhances both spectral and color Doppler signals in the left heart. In specific patient subsets, the increase in signal-to-noise ratio improved the quantitative assessment of aortic stenosis, pulmonary venous flow and mitral regurgitation.

Topics: Aortic Valve Stenosis; Contrast Media; Echocardiography, Doppler; Echocardiography, Transesophageal; Female; Humans; Male; Middle Aged; Mitral Valve Insufficiency; Polysaccharides; Prospective Studies; Pulmonary Veins; Ventricular Function, Left

To determine the magnitude and duration of peripheral vascular and cardiac Doppler signal enhancement after intravenous administration of contrast agent SH U 508A.. Suboptimal cardiac or peripheral vascular Doppler examinations were evaluated. A total of 75 intravenous bolus injections were made in 30 patients. Spectral audio Doppler intensity was measured throughout the duration of contrast effect.. No clinically relevant adverse effects were noted, and Doppler enhancement was apparent in all cases. The diagnostic confidence of the investigators when scored before and after Doppler enhancement improved from 35% to 91% (P < .05). Doppler intensity increased more than 16 dB in all vascular regions investigated (P < .05). The contrast effect lasted for more than 120 seconds in the peripheral vascular and cardiac groups at equivalent doses.. Intravenously administered SH U 508A is effective in markedly increasing cardiac, femoral arterial, and transcranial (cerebral arterial) Doppler signal intensity. The effect improves the clinical diagnostic confidence in cases of suboptimal unenhanced Doppler examinations.

Topics: Cerebral Arterial Diseases; Contrast Media; Echocardiography, Doppler; Female; Femoral Artery; Humans; Injections, Intravenous; Male; Middle Aged; Mitral Valve Insufficiency; Peripheral Vascular Diseases; Polysaccharides; Ultrasonography, Doppler, Transcranial

Contrast-enhanced 2-dimensional echocardiography without color Doppler did not result in complete filling of the left ventricular cavity in 21 patients studied. However, contrast-enhanced color Doppler was very effective and provided complete opacification of the left ventricular cavity in 20 of these 21 patients.

Topics: Adult; Aged; Aged, 80 and over; Cardiac Volume; Contrast Media; Echocardiography; Echocardiography, Doppler, Color; Female; Heart Diseases; Heart Ventricles; Humans; Image Enhancement; Male; Middle Aged; Mitral Valve Insufficiency; Polysaccharides; Stroke Volume; Thrombosis

The analysis of the pulmonary venous flow Doppler pattern can assist in the determination of the severity of mitral regurgitation and, in conjunction with transmitral flow pattern, the assessment of left ventricular diastolic dysfunction. In about one third of the cases, however, transthoracic ultrasonography is not able to record an adequately analyzable pulmonary venous flow pattern. The aim of the study was to examine and compare the effect of the echo-enhancing agent Levovist on the pulsed-wave Doppler flow quality of the transthoracically (TTE) and transesophageally (TEE) recorded pulmonary venous flow. In 26 consecutive patients, a qualitative (score system) and quantitative analysis of the pulmonary venous flow pattern was obtained before and after peripheral venous injection of Levovist at concentrations of 200 mg/ml (low dose) and 400 mg/ml (high dose). The number of measurable studies for the antegrade pulmonary venous flow increased after Levovist from 85% to 96% for TTE and from 96% to 100% for TEE. The retrograde flow as seen by TTE was adequately analyzable in only 45% before and in 73% after injection of Levovist (p < 0.02). Before any contrast enhancement, the retrograde pulmonary venous flow recorded by TEE could be analyzed in 77% of the patients with the percentage increasing to 88% and 92% after administration of a low and high dose of Levovist, respectively (p < 0.05). In particular, the quality score of the retrograde flow was significantly altered by the administration of Levovist (increase from 1.8 +/- 1.0 to 2.6 +/- 1.1 (low dose Levovist), p < 0.05 and to 2.7 +/- 1.3 (high dose Levovist). p < 0.05). The pulsed-wave Doppler evaluation by TTE without Levovist underestimated the velocities of the antegrade and retrograde pulmonary venous flow After administration of Levovist, the recorded values are comparable to those obtained by TEE. An analogous pattern is encountered when quantifying the duration of the retrograde flow component. Thus, the peripheral venous injection of Levovist leads to an improved quality of the pulmonary venous flow Doppler signal recorded by TTE. Qualitatively and quantitatively the values recorded by TTE after administration of Levovist are comparable to those of the TEE technique without an echo-enhancing agent.

Topics: Adult; Aged; Blood Flow Velocity; Contrast Media; Dose-Response Relationship, Drug; Echocardiography, Doppler; Echocardiography, Transesophageal; Female; Humans; Image Enhancement; Injections, Intravenous; Male; Middle Aged; Mitral Valve Insufficiency; Polysaccharides; Pulmonary Veins; Sensitivity and Specificity; Ventricular Function, Left

The saccharide ultrasound contrast agent SHU 508 A was used to test the hypothesis that an intravenous, transpulmonary contrast method can enhance color Doppler flow signals in the left atrium in a clinically useful manner.. Color Doppler display of mitral regurgitation may be unreliable because of variable signal to noise ratios that are at times poor. Traditional contrast agents enhance color Doppler flow signals in the right heart chambers. This study describes our observation of a recently developed contrast agent, SHU 508 A, capable of pulmonary transit after peripheral venous injection.. Control subjects (n = 10) and patients with suspected mitral regurgitation (n = 23) were studied by color Doppler flow imaging before and after 3-g intravenous doses of SHU 508 A. Reference grading of mitral regurgitation (0 to 3) was formulated from left ventricular angiography. In the four-chamber view of the left atrium, we selected for analysis the systolic frame with the maximal retrograde jet of mitral regurgitation (aliased/blue) and the diastolic frame with the maximal color coding from anterograde pulmonary venous flow (red) for planimetry and for grading the intensity of the color Doppler signal (0 to 5).. The score of the color Doppler signal intensity increased by > or = 2.5 after 3 g of SHU 508 A (p < 0.001). Flow detection improved, as shown by the increased jet area of mitral regurgitation (> or = 170%), after 3 g of SHU 508 A (3 +/- 3 vs. 12 +/- 8 cm2, p < 0.001) and by a > or = 200% increase in normal anterograde flow area (p < 0.001) in both the mitral regurgitation group and the control group. After contrast enhancement, the correlation between angiographic grading and the relation of jet area to the left atrial area increased from r = 0.79 to r = 0.91.. Contrast-mediated increased echogenicity of the left atrial blood pool improves the signal to noise ratio of Doppler images of mitral regurgitation and anterograde atrial flow. The technique is safe and simple and seems to minimize variability due to instrument design and anatomic signal attenuation.

Topics: Adult; Aged; Atrial Function, Left; Blood Flow Velocity; Case-Control Studies; Contrast Media; Echocardiography, Doppler; Evaluation Studies as Topic; Female; Humans; Image Enhancement; Injections, Intravenous; Male; Middle Aged; Mitral Valve Insufficiency; Polysaccharides